DK1608362T3 - Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse - Google Patents

Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse

Info

Publication number
DK1608362T3
DK1608362T3 DK03770970T DK03770970T DK1608362T3 DK 1608362 T3 DK1608362 T3 DK 1608362T3 DK 03770970 T DK03770970 T DK 03770970T DK 03770970 T DK03770970 T DK 03770970T DK 1608362 T3 DK1608362 T3 DK 1608362T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
composition containing
active compound
stabilized pharmaceutical
amorphous active
Prior art date
Application number
DK03770970T
Other languages
Danish (da)
English (en)
Inventor
Andrej Bastarda
Mateja Salobir
Rok Grahek
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1608362(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Application granted granted Critical
Publication of DK1608362T3 publication Critical patent/DK1608362T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK03770970T 2002-10-11 2003-10-10 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse DK1608362T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PCT/EP2003/011265 WO2004032920A1 (en) 2002-10-11 2003-10-10 Stabilized pharmaceutical preparation comprising an amorphous active substance

Publications (1)

Publication Number Publication Date
DK1608362T3 true DK1608362T3 (da) 2007-05-14

Family

ID=32091984

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03770970T DK1608362T3 (da) 2002-10-11 2003-10-10 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse
DK200700025U DK200700025U4 (da) 2002-10-11 2007-01-25 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK200700025U DK200700025U4 (da) 2002-10-11 2007-01-25 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse

Country Status (21)

Country Link
US (2) US20040077708A1 (de)
EP (1) EP1608362B1 (de)
CN (1) CN100372529C (de)
AR (1) AR041588A1 (de)
AT (2) ATE354362T1 (de)
AU (1) AU2003280361B2 (de)
CY (1) CY1106608T1 (de)
CZ (1) CZ17610U1 (de)
DE (2) DE60312049T2 (de)
DK (2) DK1608362T3 (de)
ES (1) ES2285205T3 (de)
FI (1) FI7617U1 (de)
ME (1) ME00514B (de)
PT (1) PT1608362E (de)
RS (1) RS51819B (de)
RU (1) RU2358727C2 (de)
SI (2) SI21302A (de)
SK (1) SK5233Y1 (de)
TW (1) TWI320709B (de)
UA (1) UA85544C2 (de)
WO (1) WO2004032920A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
JP4739672B2 (ja) 2001-12-21 2011-08-03 ネクター セラピューティクス 湿気のバリアを有するカプセルパッケージ
PL1653930T3 (pl) * 2003-08-05 2008-06-30 Zentiva Ks Sposoby stabilizacji atorwastatyny
AU2004317570B2 (en) 2004-03-17 2011-01-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2582449A1 (en) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Amorphous atorvastatin calcium
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (de) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
JP2010534644A (ja) * 2007-07-27 2010-11-11 シプラ・リミテッド 医薬組成物およびその製造方法
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (de) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Einheitsdosenverpackung
EP2522348B1 (de) 2009-12-25 2016-05-25 Sawai Pharmaceutical Co., Ltd. Atorvastatinhaltiges beschichtetes präparat
WO2013072770A2 (en) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
EA201791737A1 (ru) * 2015-02-03 2018-03-30 КАДМОН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Стабильные составы триентина
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (de) 2015-12-21 2017-06-28 Hexal AG Pharmazeutische zusammensetzung mit atorvastatin oder einem salz davon
US11968975B2 (en) 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (de) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DK0783301T3 (da) * 1994-09-30 1999-08-02 Becton Dickinson Co Fremgangsmåde til udformning og pakning af iontoforetiske medikamentleveringsplastre og lignende med henblik på forøgelse a
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
ATE418979T2 (de) * 2000-06-09 2009-01-15 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
HRP20020950A2 (en) * 2000-06-09 2004-12-31 Lek Tovarna Farmacevtskih Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (de) 2001-03-16 2002-09-18 Pfizer Products Inc. Ausgabeeinheit für sauerstoff-empfindlichen Medikamenten

Also Published As

Publication number Publication date
ATE354362T1 (de) 2007-03-15
WO2004032920A1 (en) 2004-04-22
CY1106608T1 (el) 2012-01-25
CN1703215A (zh) 2005-11-30
EP1608362B1 (de) 2007-02-21
DK200700025U1 (da) 2007-06-08
DE60312049T2 (de) 2007-10-04
CZ17610U1 (cs) 2007-06-18
AT10424U1 (de) 2009-03-15
RS51819B (sr) 2011-12-31
ES2285205T3 (es) 2007-11-16
FI7617U1 (fi) 2007-09-28
AU2003280361A1 (en) 2004-05-04
DE20321455U1 (de) 2007-05-24
US20040077708A1 (en) 2004-04-22
CN100372529C (zh) 2008-03-05
DK200700025U4 (da) 2008-03-14
SI21302A (sl) 2004-04-30
UA85544C2 (ru) 2009-02-10
RU2358727C2 (ru) 2009-06-20
ME00514B (me) 2011-10-10
RS20050273A (sr) 2007-06-04
SK50062007U1 (en) 2009-03-05
TWI320709B (en) 2010-02-21
TW200501947A (en) 2005-01-16
DE60312049D1 (de) 2007-04-05
US20090012150A1 (en) 2009-01-08
RU2005114485A (ru) 2006-01-27
SK5233Y1 (en) 2009-09-07
EP1608362A1 (de) 2005-12-28
FIU20070036U0 (fi) 2007-01-26
AR041588A1 (es) 2005-05-26
AU2003280361B2 (en) 2009-02-26
SI1608362T1 (sl) 2007-12-31
PT1608362E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
DK1660104T3 (da) Farmaceutisk formulering indeholdende lanthanforbindelser
NO20053076D0 (no) Farmasoytisk formulering med en uloselig aktiv forbindelse.
DE50309032D1 (de) Fungizide wirkstoffkombinationen
FI7617U1 (fi) Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
DK1558585T3 (da) Neurologisk aktive forbindelser
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
FI20031078A7 (fi) Antibioottisesti oletiivisia farmaseuttisia koostumuksia
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
DK1666473T3 (da) Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens
ITFI20020144A1 (it) Formulazioni topiche stabilizzate contenenti ketoprofene.
EP1581196A4 (de) Säurelabile arzneimittelzusammensetzungen
ITTO20020672A1 (it) Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale
AU2003238896A1 (en) Stabilized pharmaceutical compositions containing benzimidazole compounds
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
AU2003240741A1 (en) Calixarenes for use as excipient for an active substance
ITMI20011457A0 (it) Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
NO20044164L (no) Farmasoytiske sammensetninger
NO20025959D0 (no) Dispenser for tanntråd
ITMI20020639A1 (it) Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
SE0200449D0 (sv) Pharmaceutical formulation
SE0201660D0 (sv) Pharmaceutical formulation
DOP2002000508A (es) Composición farmaceutica